Last Updated: 8 September 2026
Forus, an AI healthcare company founded by Sahir Jaggi, is building software to help patients start prescribed medicines faster. The platform handles administrative work that often begins after a doctor writes a prescription, including insurance approvals, financial assistance, and pharmacy coordination. The focus is the gap between prescribing a drug and actually receiving it.
Getting a prescription does not always mean treatment begins quickly. A 2026 study published in JAMA Health Forum analyzed more than 205,000 branded drug prescriptions that initially faced prior authorization rejection. Only 35% were processed within one day, while 54% were eventually approved. For prescriptions that took longer than a day, the median processing time was six days.
Forus has raised $150 million in Series C financing at a $3 billion valuation. Bain Capital Ventures led the round, with all of the company’s existing institutional investors reinvesting. Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel also participated. The financing brings Forus’ total funding to more than $300 million and triples its valuation just months after its Series B.
Forus works on the steps that follow a doctor’s decision to prescribe a medicine. For expensive or complex treatments, patients and medical practices may still need to deal with insurance authorization, financial assistance programs, pharmacy coordination, and other administrative requirements. Those steps can delay treatment.
The company says one in three people prescribed medication for a high cost or complex condition never receives a first dose. These difficulties can also affect which medicines doctors prescribe, because physicians may turn to older treatments when they know patients can obtain them more easily.
Forus is trying to automate much of that process through a network connecting doctors, pharmacies, insurers, and biopharmaceutical companies. Its platform is used by healthcare providers across all 50 U.S. states and has treated patients in 85% of residential ZIP codes. According to the company, more than one third of providers have adopted the platform in its first launched specialty, while several other specialties have reached double digit adoption among providers nationwide.
“Forus is becoming how new medicine reaches people in America. We have backed the company since its seed, and in that time the largest companies in medicine have turned to it to bring their newest medicines to patients. The next era of medicine will run on the AI-powered network Forus is building.”
Kevin Zhang, General Partner at Bain Capital Ventures
Forus plans to use the new capital to bring its platform into more medical specialties and care settings. The company also wants its AI agents to handle more of the work that takes place between a clinical decision and the moment a patient begins treatment. The expansion is intended to cover the full treatment process.
Hiring is another stated priority. Forus plans to increase investment in its team as it expands the platform across the country and supports more healthcare providers and patients.
The company is also increasing its work with the pharmaceutical industry. Forus currently works with nine of the world’s 15 largest biopharma companies, along with a number of growing biotechnology companies. It plans to extend its role further across the drug development process, from medicines entering human testing to their eventual use by patients who need them.
Jaggi founded Forus in 2023 under the original name Tandem. Based in New York, the company was created to automate administrative work involved in helping patients gain access to prescribed medicines.
The platform assigns an AI agent to each prescription. In simple terms, the software acts like a digital case manager, reviewing information such as a patient’s medical history, insurance coverage, and financial situation before determining what administrative steps need to happen next. These can include insurance authorization, financial assistance, and coordination with pharmacies.
Forus embeds the system into healthcare provider workflows and offers it at no cost to doctors or patients. The company says its agents use clinical models, specialized AI systems, and knowledge gathered from millions of cases to decide how to move prescriptions through the process. The goal is to reduce manual administrative work for medical practices.
Because Forus is involved in the process through which prescriptions reach patients, the platform also collects information about where patients encounter delays and how medicines are used outside clinical trials. Biopharma companies can use that information when planning research and preparing the launch of new treatments.
“We are putting the Forus platform in every doctor’s office in the country, so every disease is treated with the best medicine science can offer. Medicine is advancing faster than at any point in history, increasing the urgency to make sure those advances reach the people they're meant for. We are building Forus to ensure science is the only limit to medicine.”
Sahir Jaggi, CEO and founder of Forus
Bain Capital Ventures led the Series C and has backed Forus since its seed round. Every existing institutional investor participated again, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel.
The financing comes only months after Forus announced its Series B. The new $3 billion valuation is three times the company’s valuation at that point. With the Series C completed, Forus says it has now raised more than $300 million in total.
